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Abstract
Aberrant immune response and changes in the gut microflora are the main causes of inflammatory
bowel disease (IBD). Peptidoglycan recognition proteins (Pglyrp1, Pglyrp2, Pglyrp3, and Pglyrp4)
are bactericidal innate immunity proteins that maintain normal gut microbiome, protect against
experimental colitis, and are associated with inflammatory bowel disease in humans. Nod2 is an
intracellular bacterial sensor and may be required for maintaining normal gut microbiome.
Mutations in Nod2 are strongly associated with Crohn's disease, but the causative mechanism is
not understood, and Nod2 role in ulcerative colitis is not known. Because IBD is likely caused by
variable multiple mutations in different individuals, in this study we examined the combined role
of Pglyrp3 and Nod2 in the development of experimental colitis in mice. We demonstrate that a
combined deficiency of Pglyrp3 and Nod2 results in higher sensitivity to dextran sodium sulfate
(DSS)-induced colitis compared with a single deficiency. Pglyrp3−/−Nod2−/− mice had decreased
survival and higher loss of body weight, increased intestinal bleeding, higher apoptosis of colonic
mucosa, elevated expression of cytokines and chemokines, altered gut microbiome, and increased
levels of ATP in the colon. Increased sensitivity to DSS-induced colitis in Pglyrp3−/−Nod2−/−
mice depended on increased apoptosis of intestinal epithelium, changed gut microflora, and
elevated ATP. Pglyrp3 deficiency contributed colitispredisposing intestinal microflora and
increased intestinal ATP, whereas Nod2 deficiency contributed higher apoptosis and
responsiveness to increased level of ATP. In summary, Pglyrp3 and Nod2 are both required for
maintaining gut homeostasis and protection against colitis, but their protective mechanisms differ.
INTRODUCTION
Mammalian gastrointestinal tract is inhabited by thousands of microbial species that exist in
a mutually beneficial relationship with the host. The gut microflora influences normal
development of the host immune system, prevents colonization and damage induced by
opportunistic bacteria, and regulates development and repair of the intestinal mucosa (1-4).
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The host immune system along with environmental factors, in turn, shapes the composition
of the microflora. Crohn's Disease (CD) and ulcerative colitis (UC) are common
inflammatory bowel diseases (IBD) and are associated with deficiencies in the host immune
system and with changes in gut microflora (5, 6). Host genetic factors involved in microbial
recognition and immune responses are associated with IBD; however, the specific genes and
their precise role in the development of both CD and UC remain mostly unknown (7-10).
Similarly, the precise changes in the microflora and their role in the pathogenesis of IBD are
not clearly understood (4-6).
Peptidoglycan Recognition Proteins (PGRP or Pglyrp) are innate immunity proteins that are
conserved from insects to mammals, recognize the bacterial cell wall component
peptidoglycan, and are antibacterial (11-13). Mammals have four Pglyrps, Pglyrp1, Pglyrp2,
Pglyrp3, and Pglyrp4 (14, 15); Pglyrp1 is expressed in polymorphonuclear leukocytes,
whereas Pglyrp2, Pglyrp3, and Pglyrp4 are expressed in epithelial cells of many organs,
including salivary glands, throat, tongue, esophagus, stomach, and intestine (15-17). All
mammalian Pglyrps are secreted proteins and are bactericidal for both Gram-negative and
Gram-positive bacteria (12, 17-19). Pglyrp2 is also an amidase that hydrolyzes bacterial cell
wall peptidoglycan (20, 21).
Pglyrps are important for maintaining a normal gut microbiome and for protection against
experimental colitis (22). Pglyrp1−/−, Pglyrp2−/−, Pglyrp3−/−, and Pglyrp4−/− mice are all
more sensitive to experimental (DSS-induced) colitis than WT mice (22). DSS-treated
Pglyrp-deficient mice show a greater loss of body weight, more severe intestinal bleeding,
more severe colon pathology, hyperplasia of the lamina propria, and loss of colonic
epithelial cells (22). These changes are accompanied by higher production of IFN-γ and
increased numbers of NK cells in the colon (22). In the absence of Pglyrps the gut flora
changes to a more damaging, proinflammatory microbiome and these changes are
responsible for the increased sensitivity to colitis in Pglyrp-deficient mice (22).
Pglyrps also modulate sensitivity to other inflammatory diseases. Pglyrp2 protects mice
against psoriasis-like skin inflammation (23) and is required for the development of
experimental arthritis (24), whereas Pglyrp3 and Pglyrp4 protect mice against atopic
dermatitis (25). By contrast, Pglyrp1 has a pro-inflammatory effect in three mouse models
of inflammatory skin diseases (psoriasis, atopic dermatitis, and contact dermatitis) (23, 25)
and in experimentally induced asthma (26), but has anti-inflammatory effect in
experimentally induced arthritis (24). Thus, each Pglyrp has a unique role in the
development of different inflammatory diseases, and for this reason Pglyrps do not
compensate for each other in mice deficient in a single Pglyrp. These unique effects of each
Pglyrp are most likely based on their different effects on the microbiome (22). Moreover,
genetic variants in human Pglyrp1, Pglyrp2, Pglyrp3, and Pglyrp4 genes are associated with
CD and UC (27). Several of these Pglyrp polymorphisms result in missense amino acid
changes, which may indicate a role of the Pglyrp proteins in modulating sensitivity to colitis
in humans (27).
Nod2 is a member of the NLR family of cytosolic receptors, is expressed in antigen-
presenting cells, such as monocytes (28) and dendritic cells (29), and also in structural cells
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such as intestinal epithelial cells (30), and is involved in host immune responses (31-33).
Nod2 is an intracellular sensor for muramyl dipeptide, a bacterial peptidoglycan fragment
(34, 35), and activation of Nod2 results in the activation of NF-κB and MAP kinase
signaling cascades, followed by the synthesis and release of proinflammatory cytokines,
chemokines, and antimicrobial peptides (33, 36). Nod2 was the first susceptibility gene
identified for CD and common homozygous or compound heterozygous mutations in Nod2
increase susceptibility to CD by 20-fold (37-39). However, the functional role of Nod2 in
CD remains unexplained, primarily because CD is characterized by increased inflammation
in the intestine, whereas, Nod2 mutations associated with CD result in reduced activation of
NF-κB and decreased production of inflammatory mediators after stimulation with muramyl
dipeptide (35, 40). Studies in both mice and humans also present variable and contradictory
roles of Nod2 in innate immune responses and in the development of intestinal
inflammation. In few studies that examined the role of Nod2 in ulcerative colitis the data are
also contradictory. Earlier results show no difference between WT and Nod2−/− mice in the
sensitivity to DSS-induced colitis (41), whereas later studies show higher sensitivity of
Nod2−/− mice to similar treatment (42, 43). Genome-wide association studies have
demonstrated that CD and UC share many susceptibility loci, however a Nod2 loss-of-
function variant, which is a risk allele for CD, may have a protective effect for UC (10).
These results indicate similarities and difference in the mechanisms of disease development
between CD and UC.
Here we tested the hypothesis that deficiencies in both Pglyrp3 and Nod2 synergize in
increasing the sensitivity to experimental colitis, because both Pglyrp3 and Nod2 recognize
the bacterial component peptidoglycan and play a role in maintaining normal intestinal
microflora (22, 43-46). We demonstrate that Pglyrp3−/−Nod2−/− double knockout mice are
more sensitive to DSS-colitis than Pglyrp3−/− and Nod2−/− single knockouts. The increased
susceptibility to colitis in Pglyrp3−/−Nod2−/− mice is accompanied by increased apoptosis of
epithelial cells in the colon, elevated expression of chemokines and cytokines, changes in
gut bacteria, and higher levels of ATP in the colon. Our data indicate that Pglyrp3
deficiency is mainly responsible for the change to colitis-predisposing gut bacteria and
higher ATP, whereas Nod2 deficiency is mainly responsible for the higher apoptosis in the
colon and responsiveness to higher levels of ATP. Our data also show that the lack of Nod2
expression in bone marrow-derived cells combined with expression of Nod2 in structural
(radio-resistant) cells predisposes Pglyrp3−/− mice to very severe colitis. We conclude that
Pglyrp3 and Nod2 deficiencies enhance sensitivity to experimental colitis through different
mechanisms, which are synergistic.
MATERIALS AND METHODS
Mice
Pglyrp3−/− (22) and Nod2−/− (24, 41) mice on BALB/c background were described
previously. Pglyrp3−/− mice were crossed with Nod2−/− mice to generate the homozygous
double knockout Pglyrp3−/−Nod2−/− mice. Deletion of the Pglyrp3 and Nod2 genes was
confirmed by PCR analysis of genomic DNA (22, 24). Pglyrp3−/−Nod2−/− mice were viable,
bred normally, and produced the expected male to female ratios and similar litter size as the
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WT mice. They had similar weight as WT mice and developed normally with no obvious
defects. Their major internal organs had normal macroscopic appearance and normal
histological appearance on hematoxylin/eosin stained sections. The original colony founder
WT BALB/c mice were obtained from Harlan-Sprague-Dawly. WT germ-free mice (Swiss
Webster female) were obtained from Taconic Farms (Hudson, NY).
All WT and knockout mice were on BALB/c background, female, 8-9 week-old, bred and
kept under conventional pathogen-free conditions in the same room in our facility to
minimize the influence of differences in the environment. For each experiment, mice from
several different cages and breeder pairs were used. We did not use WT and homozygous
knockout littermates from heterozygous breeding pairs for three reasons: first, this strategy
cannot be used for double knockout mice; second, this strategy may skew the results to the
particular microflora present only in this breeding pair; and third, the effect of Pglyrps on
the composition of the microbiome is not instantaneous, but takes time, and stabilization of
microbiome characteristic of a given mutant strain takes more than one generation. To avoid
changes in microbiome that could accumulate over extended period of time, we backcross
our mutant mice to WT females once every other year and re-derive our homozygous
knockout breeding pairs. The latter strategy also minimized genetic drift in the population.
The BALB/c background of knockout mice and their negative status for all common viral
and bacterial pathogens and parasites (including negative PCR stool tests for mouse
Norovirus) were confirmed as previously described (24). The Indiana University School of
Medicine–Northwest Institutional Animal Care and Use Committee approved all
experiments with mice.
Colitis model in conventional and germ-free mice
Experimental colitis was induced in WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice
with 5% DSS (dextran sulfate sodium, MP Biomedical) in drinking water (47). DSS-induced
intestinal inflammation is a well-established animal model for colitis and its manifestations
include bloody diarrhea, weight loss, shortening of the colon, mucosal ulceration, and
epithelial dysplasia. Manifestations such as predominant left-sided colitis, epithelial
dysplasia and lack of granulomas are similar with ulcerative colitis; however, the complexity
of the human disease is not completely reproduced in the DSS model (47). The development
and severity of colitis was evaluated as previously described (22), using: (a) mortality; (b)
weight loss; and (c) stool and rectal bleeding scores of 0-16. For evaluation of
histopathology, untreated control mice and mice treated with 5% DSS were sacrificed on
day 7, proximal and distal sections of the colon were fixed in 10% buffered formalin,
embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin and
scored for hyperplasia, loss of crypts, infiltration of immune cells, loss of epithelium, loss of
goblet cells, and extent of ulceration, to evaluate severity of colitis. The scoring scale was
from 0 to 5, with 0 being no change and 5 being the greatest change.
To determine the role of gut microflora in the development of colitis, female WT germ-free
mice, 4 to 5 week-old, maintained under sterile conditions, were treated with sterile 4% DSS
in drinking water and gavaged daily into the stomach with 12 mg stools from WT, Nod2−/−,
Pglyrp3−/−, or Pglyrp3−/−Nod2−/− mice, prepared as previously described (22). Briefly, fresh
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stools were collected form 12 mice/strain, which were obtained from six different breeding
parents (2 mice from 6 different parents for each strain), and kept in separate cages after
weaning. This strategy minimizes the variability observed between different litters due to
parent-to-parent and cage-to-cage differences. Stools were immediately resuspended in 0.2
ml of reduced anaerobic medium and frozen at −80oC until use. Development of colitis was
monitored as described above.
To determine whether gut microflora from Pglyrp3−/− mice was also predisposing to colitis
in Nod2−/− mice, an established non-germ-free model (48, 49) was used, in which
Nod2−/−mice were depleted of their intestinal microflora with a 3-week treatment with
antibiotics in drinking water (containing 0.33 mg/ml ciprofloxacin, 1.25 mg/ml
metronidazole, and 20 mg/ml Kool-Aid mix), followed by 2 days of sterile drinking water,
followed by treatment with sterile 4% DSS in drinking water and daily gavages into the
stomach with 12 mg stools from Pglyrp3−/− or WT mice. Development of colitis was
monitored as described above.
Intestinal permeability
WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice were given 5% DSS in drinking
water and on days 0, 3, 6, and 7 mice were gavaged into the stomach with FITC-dextran
solution (MW 4000, Sigma) at 0.6 g/kg body weight and sacrificed 4 h later. FITC-dextran
in the serum was measured in duplicate samples with a fluorescence spectrophotometer. The
concentration of FITC-dextran in μg/ml was determined using a standard curve generated
with serial dilutions of FITC-dextran.
Cell proliferation
To determine the numbers of proliferating cells, WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−
Nod2−/− were given 5% DSS in drinking water and on days 0 and 4 mice were injected
intraperitoneally with bromodexoyuridine (BrdU, Sigma) at 2 mg/mouse, twice at 12 h
intervals. Mice were sacrificed 12 h after the second injection. Proximal sections of the
colon were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained
with BrdU In-Situ Detection Kit (BD Pharmingen) and numbers of BrdU-positive cells per
500 epithelial cells were counted for each section.
TUNEL and cleaved caspase-3 staining and inhibition of cleaved caspase-3
The numbers of apoptotic cells in the colon were determined by TUNEL-labeling and by
staining for cleaved caspase-3. WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice were
given 5% DSS in drinking water and on days 0 and 4 mice were sacrificed. Proximal
sections of the colon were fixed in 10% buffered formalin, embedded in paraffin, and
sectioned. TUNEL-positive cells were detected by DeadEnd Colorimetric TUNEL System
(Promega). Cleaved caspase-3 positive cells were detected using rabbit monoclonal antibody
(clone 5A1E, Cell Signaling) and VECTASTAIN ABC Kit with DAB substrate Kit.
TUNEL-positive or cleaved caspase-3-positive cells and total epithelial cells were counted
on the entire section and percent of TUNEL-positive or cleaved caspase-3-positive cells
were calculated.
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To confirm the role of cleaved caspase 3 in the development of DSS-colitis, Pglyrp3−/−
Nod2−/− mice were given 5% DSS in drinking water and gavaged daily into the stomach
with the caspase inhibitor, Q-VD-Oph (R&D Systems, OPH001), at 80 µg/mouse/day or
with 10% DMSO in PBS. The development of colitis was monitored as described in the
Colitis Model section. To determine the effect of the caspase inhibitor, Q-VD-Oph, on
apoptosis, Pglyrp3−/− Nod2−/− mice were treated with 5% DSS in drinking water and
gavaged daily with caspase inhibitor (80 μg/mouse/day) or vehicle control (10% DMSO in
PBS). On day 4, proximal and distal regions of the colon were fixed in 10% buffered
formalin, embedded in paraffin, and sectioned. TUNEL-positive cells were detected by
DeadEnd Colorimetric TUNEL System (Promega). TUNEL-positive cells and total
epithelial cells were counted on the entire section and percent of TUNEL-positive were
calculated.
DSS-treated gavaged mice show a delay in the onset of colitis and mortality compared with
DSS-treated non-gavaged mice, because gavaged mice drink less DSS-containing water, and
thus consume less DSS per day. Mice are reluctant to drink DSS-containing water and
frequent gavaging provides mice with some fluid, and thus allows them to avoid drinking as
much DSS-containing water as they would drink without gavaging. This shift in the onset of
colitis and mortality did not affect our conclusions, because in each experiment we
compared identically treated mice, i.e., all non-gavaged, or all on the same gavage regimen.
Inflammatory arrays
RNA was isolated from individual colons of WT, Nod2−/−, Pglyrp3−/− and
Pglyrp3−/−Nod2−/−mice, untreated or treated with 5% DSS for 48, 72, and 96 h, using the
TRIZOL method (InVitrogen), followed by digestion with RNAse-free DNAse (Qiagen) and
purification on RNeasy spin columns using RNeasy Mini Kit (Qiagen) (22, 23, 26).
Quantitative real-time reverse transcription (qRT-PCR) was used to quantify the amounts of
mRNA in the colon using Mouse Inflammatory Arrays (Qiagen/SA Biosciences) or
individual primer sets for some genes, with pooled cDNA from 3 mice/group, in 3 separate
experiments (total 9 mice per group). For each gene, ΔCt was calculated followed by
normalization to 5 housekeeping genes (Hsp90ab1, Gusb, Hprt1, Gapdh, and Actb) included
in each array, followed by calculation of ΔΔCt for each gene: ΔΔCt = ΔCt1 – ΔCt2, where
ΔCt1 is for DSS-treated mice and ΔCt2 is for untreated mice, using the program provided by
Qiagen/SA Biosciences. This calculation gives the fold increase in expression of each gene
in the treated mice versus untreated mice. The genomic DNA contamination controls,
reverse transcription controls, and positive PCR controls were included in each array and
were all passed. Additional controls to assure amplification from RNA, but not from
possible contaminating DNA included parallel reaction sets from which reverse transcriptase
was omitted, and which showed no amplification. The results were reported as mean fold
increases after DSS treatment (treated/untreated) for all groups of mice and the entire data
sets were deposited in NCBI GEO (accession number GSE47588). In some experiments, the
expression of additional genes was measured by the same procedure using sets of qRT-PCR
primers from SA Biosciences (IL-6, Nod2, Pglyrp1, Pglyrp3, Pglyrp4) or designed by us
(24).
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Stool flora analysis by qPCR
The abundance of specific bacterial groups in mouse stools was measured by qPCR using
group-specific primers for 16S rRNA genes as previously described (22). Briefly, 200 mg of
fresh stools (freshly defecated feces) were collected from female mice of each strain (WT,
Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/−) and immediately processed for DNA isolation
or snap-frozen at -80ºC. Stools were collected from all strains and from total of 18 mice/
strain at three time points throughout the entire period of this study (6 mice/strain each time
in 2008, 2010, and 2013). Each time for each strain mice originated from 3 different litters
from different parents, 2 mice per litter, weaned into separate cages, but all kept in the same
room in our animal facility. DNA was isolated from stools from each mouse using Qiagen
QIAamp DNA Stool Mini Kit. Abundance of all bacteria and specific bacterial groups was
determined by qPCR using 20 ng DNA and common primers for all Eubacteria or primers
specific for the following bacterial groups: Mouse Intestinal Bacteroides, Bacteroides sp.,
Eubacterium rectale/Clostridium coccoides, Clostridium leptum, Lactobacillus/Lactococcus,
Segmented filamentous bacteria, Enterobacteriaceae, and Clostridium perfringens, with
primer sequences described previously (22, 50, 51). The amounts of DNA for each bacterial
group for each mouse were calculated using comparative cycle threshold method with
common Eubacteria primers as a control. We combined the data from the three collection
time points, because there were no statistically significant differences in the abundance of
the bacterial groups tested for each strain between these three time points. The results for
WT and Pglyrp3−/− mice with DNA collected in 2008 and 2010 were reported previously
(22).
Bone marrow-derived macrophage isolation, colon and macrophage culture, activation,
and cytokine assay
Untreated WT and Nod2−/− mice were sacrificed and bone marrow was flushed from femurs
with cold RPMI. The cells were cultured overnight in RPMI-1640 supplemented with 10%
FBS and antibiotic/antimycotic mix (Sigma) at 37°C, 5% CO2. The next day non-adherent
cells were collected and cultured in complete medium with 10 ng/ml of murine colony
stimulating factor (PeproTech Inc.), in 48-well plates at 0.5 × 106 cells per well and
incubated for an additional 5 to 6 days or until they became confluent. For colon cultures,
colons were excised from untreated WT and Nod2−/− mice, washed to remove fecal material
and cut into 0.5 cm pieces. Cells and colon fragments were stimulated with diluted stools
prepared from WT or Pglyrp3−/− mice and supernatants were collected and assayed for
cytokines and chemokines, CCL-2, CXCL-9, CXCL-10, IL-6, and CXCL-1 by ELISA using
paired capture and detection antibodies and standards from R&D Systems. For stimulation,
30 mg of fresh stools were collected from 6 WT or Pglyrp3−/− mice and immediately placed
on ice and processed. For each strain, mice originated from 3 different litters from different
parents (2 mice per litter), weaned into separate cages, but all kept in the same room in our
animal facility. Stools were suspended in 5 ml of DPBS, sonicated on ice for 2 min, and
centrifuged at 30g for 2 min to remove debris. The OD660 of the supernatants was adjusted
to 1.4 and diluted superantants were used for cell activation experiments.
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ATP measurement and colitis
Fresh stools were collected from WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice, 6
to 8 mice/group from different cages, 6 pellets per mouse, and resuspended in PBS by gently
vortexing to avoid lysis of bacteria. The resuspended feces were centrifuged at 5,000 rpm,
4°C, for 15 min, and the amount of ATP in the supernatant was measured in triplicate
samples from each mouse using the ATPlite System (Perkin Elmer). To assess the effect of
ATP on the sensitivity to colitis, WT and Nod2−/− mice were treated with 5% DSS to induce
colitis and gavaged daily into the stomach with 50 μg of α,β-ATP (Sigma-Aldrich) per
mouse or with PBS. The development of colitis was monitored as described in the Colitis
Model section.
Generation of chimeric mice with bone marrow transplantation
Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice, 6 to 8 mice/recipient group, were subjected to total
body irradiation of 850 rads for marrow ablation, administered in 2 doses, 4 h apart. Bone
marrow cells were obtained from the femurs and tibias of donor Pglyrp3−/− and
Pglyrp3−/−Nod2−/−mice. 4 h after irradiation, 5 × 106 bone marrow cells were injected into
the retro orbital vein of recipient mice. Four transplanted groups were generated: Pglyrp3−/−
> Pglyrp3−/−, Pglyrp3−/− > Pglyrp3−/−Nod2−/−, Pglyrp3−/−Nod2−/− > Pglyrp3−/−Nod2−/−,
Pglyrp3−/−Nod2−/− > Pglyrp3−/−. Transplanted mice were kept in a HEPA-filtered flow
hood and given sterilized food and water (52). For the first four weeks mice were given
filtered water with 15 g/L sucrose, 220 μg/ml neomycin and 25 μg/ml polymyxin B, and
then switched to filtered water. To re-establish the recipient gut microflora, 24 h after the
end of antibiotic treatment Pglyrp3−/− and Pglyrp3−/−Nod2−/−mice were colonized with
microflora from Pglyrp3−/− or Pglyrp3−/−Nod2−/−, respectively, by gavaging with 0.2 ml of
suspension containing 12 mg of preserved stools (22), three times over 6 days. Mice were
then allowed to recover for one week before treatment with DSS to induce colitis. We used
4% DSS, rather than 5%, to avoid early mortality, which would obscure differences in
sensitivity to colitis in these highly sensitive strains. The stool gavage procedure and
measurement of severity of colitis were done as described in the Colitis Model section. Bone
marrow reconstitution was verified at 6 weeks after irradiation and before the start of DSS.
Blood was collected from individual mice, genomic DNA was isolated using the Qiagen
Puregene Blood Core Kit and Nod2 WT and KO alleles were determined by PCR analysis
(24, 41).
Isolation of lamina propria cells and flow cytometry
Nod2−/− mice were gavaged once daily into the stomach with 50 μg of α,β-ATP per mouse
or with PBS and given 5% DSS in drinking water to induce colitis. Mice were sacrificed on
day 4 and colon lamina propria (LP) cells were isolated as described (53). Briefly, colons
were excised, washed to remove fecal material and cut into 0.5 cm pieces. Colon pieces
were shaken in HBSS with 5% FBS and 1 mM EDTA at 37°C, 2 times for 20 min.
Epithelial cells were removed by straining through 100 μm filter and the colon tissue was
digested with 2 mg/ml collagenase D (Worthington T3), 40 μg/ml DNAse I (Sigma
DN25-1G) in RPMI-1640 supplemented with 10% FCS for 80 min. The colon LP cell
suspensions were obtained by passing the digested tissue through 100 μm and then 40 μm
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filters, centrifuging, and resuspending in RPMI-1640 with 5% FBS. Colon LP cells were
stained with the following fluorochrome-conjugated antibodies in different combinations:
CD45-Vioblue, CD3-PE, CD8-APC from Miltenyi; CD4-APC, CD4-Pacific Blue, IFN-γ-
PE, IL4-PE, IL10-PE, IL17-PE, and TGFβ-APC from Biolegend, and Foxp3-PE from
eBioscience. All extracellular and intracellular staining was performed as described
previously (25, 26). CD4-stained cells were fixed, permeabilized, and stained for Foxp3.
Prior to staining for cytokines, CD4-stained cells were stimulated with TPA (25 ng/ml) and
ionomycin (250 ng/ml) in the presence of the Golgi inhibitor, monensin, for 4 h at 37°C, 5%
CO2, fixed, permeabilized, and stained for cytokines (25, 26). Cells were analyzed by flow
cytometry using MACSQuant (Miltenyi) cytometer. CD3, CD4, and CD8 positive cells were
measured within the CD45 gate. IFN-γ, IL-4, IL-10, IL-17, TGFβ, and Foxp3 positive cells
were measured within the CD4 gate.
Statistical analysis
All quantitative results are presented as means ± SEM, with statistical significance of the
differences between groups determined by the two-sample one-tailed Student's t-test, except
for survival, which was analyzed using Chi-square test; p ≤ 0.05 was considered significant.
RESULTS
Pglyrp3−/−Nod2−/− mice are highly susceptible to DSS-induced colitis
To test whether Pglyrp3 and Nod2 deficiencies synergize in increasing sensitivity to colitis,
we constructed Pglyrp3−/−Nod2−/− double deficient mice and tested their sensitivity to
colitis. Colitis was induced by oral administration of 5% DSS in drinking water in WT,
Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice. Pglyrp3−/−Nod2−/− mice developed more
severe colitis than Pglyrp3−/− and Nod2−/− mice (Fig. 1). Pglyrp3−/−Nod2−/− mice had
accelerated and significantly higher mortality, accelerated and significantly greater weight
loss, and significantly higher diarrhea and intestinal bleeding than Pglyrp3−/−, Nod2−/−, and
WT mice. Pglyrp3−/− mice, as shown previously, also developed severe DSS-induced colitis
(22), however, they were less sensitive than Pglyrp3−/−Nod2−/− mice, as demonstrated by
significantly higher survival, significantly lower weight loss, and significantly less severe
intestinal bleeding than Pglyrp3−/−Nod2−/− mice (Fig. 1). By contrast, Nod2−/− mice were
far less sensitive to colitis and manifested symptoms similar to WT mice (Fig. 1). We also
evaluated histopathologic changes as a measure of the severity of colitis by scoring for
hyperplasia, loss of crypts, infiltration with inflammatory cells, loss of epithelium, loss of
goblet cells, and extent of ulceration on hematoxylin and eosin stained sections of the colon.
These histopathologic changes are characteristic for colitis. Pglyrp3−/− and
Pglyrp3−/−Nod2−/− mice had significantly higher scores for hyperplasia, loss of crypts,
infiltration with inflammatory cells, loss of epithelium, loss of goblet cells, and ulceration
than WT and Nod2−/− mice (Fig. 1B and 1C). Furthermore, Pglyrp3−/−Nod2−/− mice had
significantly higher scores for loss of crypts, loss of epithelial and goblet cells and ulceration
than WT, Nod2−/−, and Pglyrp3−/− mice (Fig. 1B and 1C). Thus, our phenotypic and
histopathologic data indicate that the double knockout Pglyrp3−/−Nod2−/− mice are more
sensitive to DSS-induced colitis than single knockouts Pglyrp3−/− and Nod2−/− and WT
mice.
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Pglyrp3−/−Nod2−/− mice are deficient in cell proliferation and have higher apoptosis in the
intestine
DSS-colitis is an epithelial injury model of IBD and we next determined whether the higher
sensitivity of Pglyrp3−/−Nod2−/− mice to DSS-induced colitis is accompanied by changes in
the permeability of the intestine and in the rates of proliferation and apoptosis of colon
epithelial cells. In order to measure permeability changes, DSS-colitis was induced in WT,
Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice, and FITC-dextran was administered by
gavage before sacrifice. Mice were sacrificed at different time points and the amount of
FITC-dextran in the serum was measured. The concentration of FITC-dextran in the serum
was significantly higher in Pglyrp3−/−Nod2−/− mice on days 6 and 7 of DSS treatment
compared with WT, Nod2−/−, and Pglyrp3−/− mice (Fig. 2A). Pglyrp3−/− mice had
significantly higher levels of FITC-dextran on day 7 than Nod2−/−mice and on days 6 and 7
than WT mice (Fig. 2A). These results indicate that both Pglyrp3 and Nod2 contribute to the
integrity of the intestinal mucosa and a deficiency of both genes significantly increases
damage to the intestine in DSS-treated mice. However, Pglyrp3−/− mice have more
prolonged and severe damage than Nod2−/− mice.
In order to identify the changes in the intestinal mucosa that result in increased permeability
we determined the rate of colonic cell proliferation and apoptosis in DSS-treated and
untreated mice. To measure the numbers of proliferating cells, DSS-treated or untreated WT,
Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice were gavaged with BrdU and
proliferating cells were identified by immunohistochemistry. Pglyrp3−/−, Nod2−/−, and
Pglyrp3−/−Nod2−/− mice all had significantly fewer BrdU-positive cells than WT mice (Fig.
2B). Also, Pglyrp3−/− mice had significantly fewer BrdU-positive cells than Nod2−/− and
Pglyrp3−/−Nod2−/− mice (Fig. 2B). These results indicate that Pglyrp3 deficiency results in a
severe inhibition of proliferation, which most likely contributes to the sensitivity to DSS-
induced colitis in Pglyrp3−/− and Pglyrp3−/−Nod2−/−mice. By contrast, Nod2 deficiency
caused less severe decrease in proliferation (Fig. 2B), which is reflected in less severe colitis
in Nod2−/− than in Pglyrp3−/− mice (Fig. 1).
We next measured apoptosis in the colons of DSS-treated and untreated WT, Nod2−/−,
Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice using TUNEL immunohistochemistry.
Pglyrp3−/−Nod2−/−mice had significantly more TUNEL-positive cells than Pglyrp3−/−,
Nod2−/−, and WT mice and Nod2−/− mice had significantly more TUNEL-positive cells than
Pglyrp3−/− and WT mice (Fig. 2C). To further evaluate apoptosis in the intestinal epithelium
of DSS-treated Pglyrp3−/−Nod2−/− mice we assayed for cleaved caspase-3, which is the
active form of caspase-3, an enzyme essential for apoptosis. We detected cleaved caspase-3
in the intestinal mucosa of untreated and DSS-treated WT, Nod2−/−, Pglyrp3−/−, and
Pglyrp3−/−Nod2−/− mice by immunohistochemistry. DSS-treated Pglyrp3−/−Nod2−/− mice
had the highest increase of cleaved caspase-3 positive cells, significantly higher than
Pglyrp3−/−, Nod2−/−, and WT mice (Fig. 2D). DSS-treated Nod2−/− mice had significantly
higher numbers of cleaved caspase-3 positive cells than Pglyrp3−/− and WT mice (Fig. 2D).
Our TUNEL and cleaved caspase-3 data indicate that a combined deficiency in both Pglyrp3
and Nod2 results in the highest apoptosis of colonic epithelial cells and that Nod2 deficiency
has a greater contribution to this high apoptosis than Pglyrp3 deficiency.
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Because Pglyrp3−/−Nod2−/− mice were highly sensitive to DSS-colitis and had significantly
higher numbers of apoptotic epithelial cells in the colon, we next tested the effect of a
caspase inhibitor on the development of colitis in these mice. Pglyrp3−/−Nod2−/− mice were
treated with DSS and gavaged daily with the caspase inhibitor Q-VD-OPh or PBS as a
control. The caspase inhibitor significantly decreased all clinical manifestations of colitis.
Caspase inhibitor-treated Pglyrp3−/−Nod2−/− mice showed significantly higher survival and
lower weight loss and stool scores than PBS-treated control mice in response to DSS (Fig.
2E). We next determined the effect of the caspase inhibitor Q-VD-OPh on apoptosis in the
colon. The numbers of TUNEL-positive colon epithelial cells were significantly lower in
caspase inhibitor-treated than control Pglyrp3−/−Nod2−/− mice (Fig. 2E). These results
demonstrate that the caspase inhibitor Q-VD-OPh is effective in decreasing apoptosis of
intestinal epithelial cells and that apoptosis is required for the full severity of DSS-induced
colitis in Pglyrp3−/−Nod2−/− mice. However, the caspase inhibitor did not completely
abrogate the symptoms of colitis, which indicates that other factors also contribute to the
disease severity in DSS-treated Pglyrp3−/−Nod2−/− mice.
In summary, these results demonstrate that both Pglyrp3 and Nod2 are required for
maintaining a functional and intact intestinal mucosa. A single deficiency of Pglyrp3, but
not Nod2, is sufficient to make mice more sensitive to DSS-induced colitis. However, a
combined deficiency of Pglyrp3 and Nod2 synergistically increases sensitivity to DSS-
induced colitis, and increased apoptosis of intestinal epithelial cells is one of the factors
responsible for this increased sensitivity.
Pglyrp3−/−Nod2−/− mice have increased expression of inflammatory molecules
We next measured the expression of inflammatory molecules in the colon using qRT-PCR
microarrays. DSS-treated Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice had significantly higher,
but not identical, expression of mRNA for several cytokines and chemokines (Fig. 3 and
Table S1 with entire array data). Both Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice had higher
expression of Th1 and NK cell markers, IFN-γ, CXCL-9, CXCL-10, and CXCL-11; Th2
markers, CCL-7 and CCL-8; Th17 markers, CCL-2, CXCL-1, and CXCL-5, than WT and
Nod2−/− mice (Fig. 3). DSS-treated Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice also had
elevated expression of the cytokines IL-1β, IL-6, and IL-11 (which are produced by many
different cell types) compared with WT and Nod2−/− mice (Fig. 3). In addition,
Pglyrp3−/−Nod2−/− mice had significantly higher expression of TNF-α, IL-1f6, and CCR-7
than Pglyrp3−/−, WT, and Nod2−/− mice (Fig. 3). These results indicate that colitis in
Pglyrp3−/−Nod2−/− mice is accompanied by higher induction of several inflammatory
mediators, many of which are shared with the Pglyrp3−/− inflammatory profile and some
that are unique. Because expression of TNF-α, IL-1f6, and CCR-7 was higher in
Pglyrp3−/−Nod2−/− than in Pglyrp3−/− mice, these molecules may contribute to the higher
sensitivity of Pglyrp3−/−Nod2−/−mice to DSS-colitis. Several of these inflammatory gene
responses in DSS-treated Pglyrp3−/− Nod2−/− mice were Nod2-independent, because they
were similar or higher than in Pglyrp3−/−(Nod2+/+) mice (Fig. 3 and Table S1).
We determined that expression of Pglyrp1, Pglyrp2, Pglyrp3 and Pglyrp4 genes in tongue,
esophagus, and colon was similar in Nod2−/− and WT mice (data not shown). We have
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previously shown that treatment with DSS increases the expression of Pglyrp3 in the colon
(22). We further determined that the expression of Pglyrp3 in the colon in DSS-treated WT
and Nod2−/− mice was similar, and also that the expression of Nod2 in the colon was similar
in untreated or DSS-treated Pglyrp3−/− and WT mice (data not shown). These results
indicate that the colitis phenotype in Pglyrp3−/−Nod2−/− double knockout mice is not due to
changes in the expression of Pglyrp3 in a Nod2-deficient background or changes in the
expression of Nod2 in a Pglyrp3-deficient background.
Pglyrp3-dependent, but not Nod2-dependent, intestinal microflora predisposes to DSS-
colitis
Pglyrp3 is a secreted antibacterial protein and we have previously shown that Pglyrp3−/−
mice have changes in the gut bacterial flora, which are responsible for the higher sensitivity
of Pglyrp3−/− mice than WT mice to DSS-induced colitis (22). Nod2 is also involved in
innate immune responses to bacteria and Nod2−/− mice also have an altered microbial
population in the gut (43-46). Therefore, we next tested whether Pglyrp3−/−Nod2−/− mice
have additional changes in the gut microflora and whether these cumulative changes are
responsible for the higher sensitivity to colitis in the double-knockout mice. We compared
the composition of bacterial flora in the stools of WT, Pglyrp3−/−, Nod2−/−, and
Pglyrp3−/−Nod2−/− mice, by measuring the amounts of DNA for all Eubacteria and for eight
major groups of mouse intestinal bacteria using qPCR. Single and double knockout mice
had significant, but not identical changes in the composition of their bacterial flora in their
stools. The amounts of bacteria in the following bacterial groups showed significant changes
in knockout compared with WT mice: Lactobacillus and Clostridium perfringens groups in
Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice; Eubacterium rectale, Clostridium
leptum, and Enterobacteriaceae groups in Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice; and
Segmented Filamentous bacteria in Pglyrp3−/−Nod2−/− mice (Fig. 4A).
We next tested whether these changes in the microflora in Pglyrp3−/−Nod2−/− mice are
responsible for their increased sensitivity to DSS-colitis. We gavaged WT germ-free mice
daily with stools from WT, Nod2−/−, Pglyrp3−/−, or Pglyrp3−/−Nod2−/− mice and we induced
colitis with 4% DSS. Germ-free mice receiving stools from Pglyrp3−/− or
Pglyrp3−/−Nod2−/− mice were more sensitive to DSS-colitis than mice receiving Nod2−/− or
WT stools, but the sensitivity of mice receiving stools from Pglyrp3−/− or
Pglyrp3−/−Nod2−/− mice was similar. Germ-free mice gavaged with stools from
Pglyrp3−/−Nod2−/− or Pglyrp3−/− mice had significantly higher mortality, higher weight
loss, and higher stool scores than mice gavaged with Nod2−/− or WT stools, and all these
indicators were similar in germ-free mice gavaged with stools from Pglyrp3−/−Nod2−/− and
Pglyrp3−/− mice (Fig. 4B). The sensitivity to colitis of germ-free mice gavaged with stools
from WT or Nod2−/− mice was similar. These results confirm our previous results that the
increased sensitivity to DSS colitis in Pglyrp3−/− mice is due to an altered gut microflora
(22), and further demonstrate that this altered microflora contributes to a similar extent to
the increased sensitivity to DSS colitis in Pglyrp3−/− mice and in Pglyrp3−/−Nod2−/− mice.
These results also demonstrate that microflora from Nod2−/− mice does not predispose germ-
free mice to colitis compared with microflora from WT mice. Thus, these results
demonstrate that Pglyrp3−/− mice contribute colitis-predisposing flora to Pglyrp3−/−Nod2−/−
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mice, and that the additional changes in the microflora in Pglyrp3−/−Nod2−/− mice,
compared with Pglyrp3−/− mice, do not further contribute to the increased sensitivity of
Pglyrp3−/−Nod2−/− mice to colitis.
We further tested the effect of microflora from Pglyrp3−/− mice on the development of DSS-
colitis in a Nod2-deficient background. We treated Nod2−/− mice with antibiotics for 3
weeks to deplete their intestinal microflora. At the end of 3 weeks we gavaged the
antibiotic-treated mice with stools from WT or Pglyrp3−/− mice and induced colitis with oral
DSS. Nod2−/−mice receiving stools from Pglyrp3−/− mice were more sensitive to DSS-
colitis than mice receiving WT stools (Fig. 4C). The more severe colitis in Nod2−/− mice
gavaged with stools from Pglyrp3−/− mice manifested as significantly higher loss in body
weight and stool scores and significantly lower survival (Fig. 4C). These results indicate that
Pglyrp3−/− microflora is stable, Pglyrp3-dependent, and has colitis-predisposing
characteristics on both Nod2−/− and Nod2+/+ backgrounds.
Our previous results demonstrated that the gut microflora from Pglyrp3−/− mice induces
higher production of inflammatory molecules, IL-6 and CXCL-1, than WT microflora (22).
Thus, we next tested whether the response to gut bacteria from Pglyrp3−/− mice is variable
in Nod2−/− and Nod2+/+ backgrounds, because Nod2 is one of the bacterial recognition cell-
activating pattern recognition receptors, and because Pglyrp3−/−Nod2−/− mice are more
sensitive to colitis than Pglyrp3−/− mice. Colon cells and fragments or bone marrow
macrophages from WT or Nod2−/− mice were stimulated with diluted stools from WT or
Pglyrp3−/− mice, to determine whether cells from WT or Nod2−/− mice have differential
responsiveness to colitis-promoting (Pglyrp3−/−) and non-promoting (WT) stools (Fig. 4 and
ref. 22). Culture supernatants were then assayed for different cytokines and chemokines.
Stools from Pglyrp3−/− mice induced higher production of CCL-2, CXCL-9, and IL-6 in
cells from WT, but not from Nod2−/− colon cells and fragments (Fig. 5A) and higher
production of CCL-2, CXCL-1, CXCL-10, and IL-6 in WT, but not Nod2−/− bone marrow
macrophages (Fig. 5B) compared with stools from WT mice. These results confirm our
previous data that stools from Pglyrp3−/− mice are more pro-inflammatory than stools from
WT mice (22) and show that induction of these pro-inflammatory chemokines and cytokines
is significantly higher on Nod2+/+ than on Nod2−/− background. The results in Fig. 5 also
show that although the responses of cells from Nod2−/− mice are generally lower than from
WT mice (as expected), the cells from Nod2−/− mice are still responsive to bacteria
(presumably through other bacterial sensors), and also that all responses are not equally
affected, showing that some responses are Nod2-dependent and some Nod2-independent and
that cells from Nod2−/− mice are differentially responsive to stools from WT and Pglyrp3−/−
mice. For example, CXCL-10 production was not reduced in colon from Nod2−/− mice,
compared with WT mice (Fig. 5A), and bone marrow macrophages from both WT and
Nod2−/− mice produced IL-6 in response to stools only from Pglyrp3−/− mice, but not WT
mice (Fig. 5B). Moreover, several inflammatory gene responses to DSS in the entire colon
in vivo involved additional Nod2-independent signals, because many of these responses
were similar or higher in Pglyrp3−/−Nod2−/− compared with Pglyrp3−/− mice (Fig. 3 and
Table S1).
Jing et al. Page 13
J Immunol. Author manuscript; available in PMC 2015 September 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pglyrp3−/− and Pglyrp3−/− Nod2−/− mice have increased ATP in the colon, which increases
inflammatory T cells and predisposes to colitis
Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice have altered gut microflora, which contributes to
the increased sensitivity to DSS-colitis. In order to identify bacterial metabolites that may
facilitate damage to the intestine, we assayed for ATP in mouse stools, because: (i) ATP is
produced by gut microflora; (ii) ATP is known to increase sensitivity to T-cell-mediated
colitis by increasing the numbers of inflammatory Th17 cells in the intestine (54); and (iii)
we had increased expression of Th17 markers, CCL-2, CXCL-1, and CXCL-5 in the colon
of DSS-treated Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice (Fig. 3).
Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice had significantly higher levels of ATP in the stools
than WT and Nod2−/− mice (Fig. 6A). Thus, we next tested whether elevated ATP increases
the sensitivity to DSS-colitis in Nod2−/− and WT mice. We used Nod2−/− mice for these
experiments to recreate the Nod2−/− genetic background of Pglyrp3−/−Nod2−/− mice and one
aspect of Pglyrp3 deficiency (higher ATP) and we used WT mice as controls. Nod2−/− and
WT mice were treated with DSS to induce colitis, gavaged daily into the stomach with the
stable ATP analog, α,β-ATP or PBS (control), and assayed for the development of colitis.
Nod2−/− and WT mice treated with α,β-ATP showed significantly higher mortality,
significantly greater loss in body weight, and significantly higher stool scores, compared
with PBS-treated Nod2−/− and WT mice, respectively (Fig. 6B). Furthermore, Nod2−/− mice
treated with α,β-ATP had significantly higher mortality, significantly greater loss in body
weight, and significantly higher stool scores, than WT mice treated with α,β-ATP. These
results indicate that increased levels of ATP promote DSS-induced colitis in Nod2−/− and
WT mice, and that Nod2 deficiency further enhances the promoting effect of ATP on the
severity of colitis. Our results also suggest that the increased sensitivity to DSS-colitis in
Pglyrp3−/−Nod2−/− mice can be partially explained by the elevated ATP in the intestine and
that Pglyrp3 deficiency contributes the increased ATP, whereas Nod2 deficiency enhances
sensitivity to ATP and severity of colitis.
To further understand the role of elevated colon ATP levels in the increased sensitivity to
DSS-colitis of Pglyrp3−/−Nod2−/− mice, we next compared the levels of inflammatory T
cells in the colon lamina propria of DSS treated Nod2−/− mice in the presence and absence
of the stable ATP analog, α,β-ATP. Again, we used Nod2−/− mice for these experiments to
recreate Nod2−/− genetic background of Pglyrp3−/−Nod2−/− mice and one aspect of Pglyrp3
deficiency (higher ATP). The numbers of CD3+, CD4+, CD4+TGFβ+, CD4+IL-4+ (Th2),
and CD4+IL-17+ (Th17) cells were significantly higher in DSS-treated Nod2−/− mice
gavaged with α,β-ATP than in the control mice gavaged with PBS (Fig. 6C and D). There
was no significant difference in CD4+ cells expressing Foxp3+ (Fig. 6C), which is the
marker for the anti-inflammatory regulatory T (Treg) cells. These data also correlate with
our mRNA expression microarray results, which demonstrate higher expression of Th2 and
Th17 markers in Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice (Fig. 3 and Table S1).
In conclusion, a deficiency in Pglyrp3 results in high levels of ATP in the colon, and high
ATP results in increased numbers of inflammatory Th17 and Th2 cells in the colon and
causes higher sensitivity to DSS-colitis. These results suggest that in Pglyrp3−/−Nod2−/−
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mice, Pglyrp3-deficiency contributes the elevated ATP and that Nod2−/− mice respond to
higher concentration of ATP with increased numbers of inflammatory Th17 and Th2 cells
and higher sensitivity to DSS-colitis. These results offer one possible mechanism of
microbiota-induced sensitivity to colitis in Nod2−/− mice, which are generally less
responsive to bacteria than WT mice (Fig. 5), yet are more sensitive to colitis induced by
microflora from Pglyrp3−/− mice (Fig. 4C).
Lack of Nod2 in bone marrow-derived cells combined with presence of Nod2 in structural
cells predisposes Pglyrp3−/− mice to severe colitis
Pglyrp3 is expressed in epithelial cells, whereas Nod2 is expressed in both bone marrow-
derived and structural (epithelial and stromal) cells. We next determined whether the lack of
Nod2 expression in bone marrow-derived cells or structural cells was important for
enhanced sensitivity to DSS-induced colitis in Pglyrp3−/−Nod2−/− mice. We generated
Pglyrp3−/− > Pglyrp3−/−Nod2−/− and Pglyrp3−/−Nod2−/− > Pglyrp3−/− bone marrow
chimeric mice, as well as control mice, which received bone marrow cells from the same
strain of mice: Pglyrp3−/− > Pglyrp3−/− and Pglyrp3−/−Nod2−/− > Pglyrp3−/−Nod2−/−.
Chimerism was confirmed by PCR of genomic DNA and showed that blood cells from
Pglyrp3−/−Nod2−/− > Pglyrp3−/− mice contained only Nod2 KO allele, whereas blood cells
from Pglyrp3−/− > Pglyrp3−/−Nod2−/− mice contained only Nod2 WT allele (Fig. 7B). All
groups of mice were treated with DSS to induce colitis and development of colitis was
monitored. Pglyrp3−/−Nod2−/− > Pglyrp3−/− chimeras developed the most severe colitis
compared with Pglyrp3−/− > Pglyrp3−/−Nod2−/− chimeras and the control Pglyrp3−/− >
Pglyrp3−/− and Pglyrp3−/−Nod2−/− > Pglyrp3−/−Nod2−/− mice, with significantly higher
mortality, significantly higher stool scores, and significantly greater loss of body weight
(Fig. 7A). Pglyrp3−/− > Pglyrp3−/−Nod2−/− and Pglyrp3−/−Nod2−/− > Pglyrp3−/−Nod2−/−
mice had intermediate sensitivity to colitis, and Pglyrp3−/− > Pglyrp3−/− mice developed the
least severe colitis.
These results show that the lack of Nod2 expression in bone marrow-derived cells combined
with expression of Nod2 in structural (radio-resistant) cells (Pglyrp3−/−Nod2−/− >
Pglyrp3−/−) predisposes Pglyrp3−/− mice to very severe colitis, more severe than the lack of
Nod2 in both bone marrow-derived and structural cells (Pglyrp3−/−Nod2−/− >
Pglyrp3−/−Nod2−/−) or the lack of Nod2 only in structural cells (Pglyrp3−/− >
Pglyrp3−/−Nod2−/−). Also, expression of Nod2 in all cells protects from colitis, because
Pglyrp3−/− > Pglyrp3−/− mice were less sensitive to colitis than Nod2-chimeric or fully
Nod2-deficient mice, which confirms our other results in this study. Altogether, these results
further indicate that expression of Nod2 is protective against colitis, and suggest that
expression of Nod2 in bone marrow-derived cells is more important for protection against
colitis than Nod2 expression in structural cells. These results also suggest that expression of
Nod2 in structural cells has a colitis-promoting effect, but only when Nod2 is not expressed
in marrow-derived cells.
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DISCUSSION
Inflammatory bowel disease is caused by aberrant host immune responses, altered gut
microbiome, and environmental factors. Thus, there is no single cause for IBD and the exact
genetic and environmental factors that result in IBD most likely differ in different
individuals. In this study we report that a combined deficiency of two innate immunity
genes, Pglyrp3 and Nod2, results in increased sensitivity to an experimental model of colitis.
We show that Pglyrp3−/−Nod2−/− double deficient mice are more sensitive to DSS-induced
colitis than Pglyrp3−/−, Nod2−/−, and WT mice. We also confirmed our previous results
showing increased sensitivity to DSS-colitis in Pglyrp3−/− mice (22). Nod2−/− mice were
significantly less sensitive to DSS-colitis than Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice and
had similar sensitivity to WT mice, which confirms the findings of Kobayashi et al. (41), but
differs from two other studies (42, 43). These conflicting results with Nod2−/− mice are
difficult to explain and may result from differences in genetic backgrounds, gut bacteria,
environment, and/or other unknown factors.
Pglyrp3−/−Nod2−/− mice treated with DSS had high mortality, severe loss in body weight
and high stool scores. These phenotypic manifestations were accompanied by several
histopathologic changes including severe hyperplasia, loss of crypts, infiltration with
inflammatory cells, loss of epithelium, loss of goblet cells, and ulcers, which are
characteristic for colitis. Additional changes associated with colitis in Pglyrp3−/−Nod2−/−
mice were increased gut permeability, decreased colonic epithelial cell proliferation,
increased colonic epithelial cell apoptosis, increased expression of chemokines and
cytokines, changes in gut bacteria, and increased ATP in the colon. Our results demonstrate
that Nod2 deficiency contributes significantly to higher apoptosis and that Pglyrp3
deficiency contributes to higher ATP in the colon, which causes increased numbers of
inflammatory T cells and increased sensitivity to DSS-colitis. These results suggest that the
enhanced sensitivity of Pglyrp3−/−Nod2−/− mice to DSS-colitis is due to multiple factors and
that Pglyrp3 and Nod2 have both overlapping and unique contributions toward sensitivity to
colitis in the double-knockout mice.
Pglyrp3−/−Nod2−/− mice have significantly higher apoptosis in the colon, which is required
for the increased sensitivity to colitis of Pglyrp3−/−Nod2−/− mice. Deficiency in both
Pglyrp3 and Nod2 contributed to the enhanced apoptosis in the double-knockouts, however,
Nod2 deficiency had a stronger effect than Pglyrp3 deficiency. The increased sensitivity of
Pglyrp3−/−Nod2−/− mice to DSS-colitis required the protease caspase-3, an important
regulatory enzyme that activates downstream execution caspases during apoptosis.
Apoptosis is crucial for the rapid turnover of intestinal mucosal cells and for homeostasis of
the gut, and the role of caspase-3 in this process is well documented (55). The mechanism
by which Nod2 regulates apoptosis is not known. However, our results also suggest that
Nod2 deficiency in bone marrow-derived cells highly increases sensitivity to colitis, which
suggests that higher sensitivity to apoptosis of epithelial cells in Nod2−/− mice may result
from the lack of protective effects of cytokines or other factors from bone marrow-derived
cells. A recent report demonstrated that Nod2 is involved in cross talk with the apoptosis
protein, Bid, a member of the Bcl2 family, and that this interaction is required for the pro-
inflammatory function of Nod2, which involves activation of NF-κB and increased
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expression of chemokines and cytokines (56). However, data showing Nod2-Bid interaction
have not been replicated and it is not known whether this interaction regulates apoptosis.
The role of mammalian Pglyrps in apoptosis is novel for these proteins and increased
apoptotic cells may be an indirect consequence of mucosal damage by changed microflora in
Pglyrp-deficient background.
Pglyrp3−/−Nod2−/− and Pglyrp3−/− mice treated with DSS had higher expression of Th1,
Th2, and Th17 markers and higher expression of IL-1β, IL6, and IL-11, which are produced
by many cell types. These changes are most likely due to a deficiency of Pglyrp3 and altered
microflora, as they are observed in both Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice. These
results also confirm our previous discovery of a predominant role of IFN-γ and IFN-γ-
regulated chemokines, CXCL9, CXCL-10, CXCL-11, and CCL-2 in DSS-colitis in Pglyrp-
deficient mice (22). CCR-7, TNF-α, IL-1β, and IL-1f6 were significantly higher in the colon
of Pglyrp3−/−Nod2−/− than Pglyrp3−/− mice and may indicate a role for Nod2 in their
regulation. CCR7 is the receptor for CCL19 and CCL21 and influences both immune
responses and tolerance in the gut by regulating migration of T cells to lymphoid organs
(57). The role of CCR7 in Pglyrp3−/−Nod2−/− mice during DSS-colitis is not understood, but
may indicate greater trafficking of T cells in the damaged intestine. TNF-α is a common
pathogenic factor in many models of colitis and is also known to trigger apoptosis of
epithelial cells (58). Higher expression of TNF-α in Pglyrp3−/−Nod2−/− mice correlates with
higher apoptosis and may be one of the contributing factors to the increased mucosal cell
death in the double knockout mice. Synthesis of IL-1β is induced by TLRs in response to
bacteria and bacterial fragments (59) and the increased expression of IL-1β in DSS-treated
Pglyrp3−/−Nod2−/− mice may be in response to the altered gut microflora due to Pglyrp3
deficiency. IL-1f6 is a new member of the IL-1 family of cytokines and its elevated
expression is associated with the inflammatory disease psoriasis and with psoriasis-like
symptoms (60). Our results indicate that IL-1f6 expression is increased in a Nod−/− but not a
Nod+/+ background and may have a role in sensitivity to DSS-colitis in Pglyrp3−/−Nod2−/−
mice.
Pglyrp3−/−Nod2−/− mice had significant differences in the major groups of gut bacteria
compared with WT mice, and some of these changes were also common for Pglyrp3−/− and
Nod2−/− mice. Our results using germ-free mice gavaged with stools form WT, Nod2−/−,
Pglyrp3−/−, or Pglyrp3−/−Nod2−/− mice demonstrate that Pglyrp3 deficiency, but not Nod2
deficiency, contributes colitis-promoting microflora to the double-knockout mice. These
data suggest that a deficiency in Pglyrp3, but not in Nod2, is responsible for the colitis-
predisposing dysbiosis in Pglyrp3−/− Nod2−/− mice, and that Nod2 deficiency contributes
other factors further predisposing these mice to colitis. Pglyrp3-dependent microflora also
increases sensitivity to colitis in a Nod2-deficient background, which further indicates that
Pglyrp3-dependent microflora is required for the increased sensitivity to DSS-colitis in
Pglyrp3−/−Nod2−/− mice.
Our results demonstrating differences in gut microbial populations between Nod2−/− and
WT mice are in agreement with other studies (43-46). However, our results showing that
microflora from Nod2−/− mice does not increase the sensitivity to colitis in WT germ-free
mice differ from the results of Courtier-Maillard et al., who used co-housed WT mice (43).
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Moreover, differences in gut microbial populations between F2 WT and Nod2−/− littermates
were recently shown to be dependent on maternal lineage and not on the Nod2−/− deficiency
(61). It was not determined, however, whether Nod2−/− genotype influences microflora over
a longer period of time. We did not use F2 littermates in our experiments because a change
to colitis-predisposing microflora due a Pglyrp-deficiency does not happen immediately or
over a few weeks, but is established over more than one generation (Dziarski, unpublished
data). Therefore, all mice used in our experiments were derived from knockout strains that
were established after backcrossing to the same WT stock at least six months earlier and
bred in the same facility. Furthermore, in our experiments with gut microflora we used 18
mice/strain, obtained from 9 different breeding pairs for each strain (2 mice/breeding pair)
and kept in separate cages after weaning. This strategy allows stabilization of microflora and
minimizes the variability observed between different litters due to different parents and
different cages. Stools for microflora testing were collected at three time points over a 5-
year period, and there were no statistically significant differences in the abundance of the
bacterial groups tested for each strain between these three time points, which indicates stable
and genotype-dependent stool microflora over the entire 5-year period of the study.
Moreover, our results with the transfer of the predisposition to colitis to germ-free mice with
stool microflora from either Pglyrp3−/− or Pglyrp3−/−Nod2−/− mice show that Pglyrp3−/−
microflora is stable, Pglyrp3-dependent, and has colitis-predisposing characteristics on both
Nod2−/− and Nod2+/+ backgrounds.
Pglyrp3−/− and Pglyrp3−/−Nod2−/− mice had higher levels of ATP in the colon than
Nod2−/−and WT mice. Administration of a stable ATP analog to Nod2−/− and WT mice
made them more sensitive to DSS-colitis. However, Nod2 deficiency further increased
sensitivity to DSS-induced colitis in the presence of elevated ATP. Increased colitis in ATP-
treated Nod2−/− mice was accompanied by higher numbers of CD3, CD4, Th17, and Th2
cells in the colon lamina propria. Extracellular levels of ATP are tightly controlled and
elevated amounts serve as a danger signal that modulates immune functions (54, 62, 63).
High extracellular ATP induces differentiation of lamina propria T cells into Th17 cells,
which causes colitis (54) and drives inflammation in asthma (62, 63). High concentrations of
extracellular ATP also induce activation of caspase-3 and apoptosis in macrophages (64),
gingival epithelial cells (65), and anti-inflammatory Treg cells (66). ATP in the colon may
be released from injured epithelial cells or from gut bacteria, which are known to secrete
large amount of ATP (67). The most likely source of elevated ATP in Pglyrp3−/− and
Pglyrp3−/−Nod2−/− mice is the altered microbiota and not injured epithelial cells, because
elevated ATP is present in untreated mice, which have a healthy gut mucosa (22).
Accordingly, changes in the gut bacterial populations are known to modify the amount of
ATP produced in the colon (54). Collectively, these studies suggest a possible mechanism
for the role of ATP in increased sensitivity to DSS-colitis in Pglyrp3−/− and
Pglyrp3−/−Nod2−/− mice, which includes ATP-induced apoptosis of intestinal epithelial cells
and lamina propria Treg cells, and increased differentiation of lamina propria Th17 cells.
Our data demonstrate that Nod2−/− mice treated with DSS and a stable analog of ATP are
more sensitive to colitis and have increased numbers of Th17, but unchanged numbers of
Treg cells in the colon lamina propria compared with PBS-treated mice. Thus, in our model
of ulcerative colitis, ATP may regulate sensitivity to DSS-colitis through increased
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apoptosis of epithelial cells and increased differentiation of Th17 cells, but not through
increased apoptosis of Treg cells. Thus, our data suggest that a Pglyrp3 deficiency results in
elevated ATP in the colon, which drives differentiation of inflammatory Th17 cells and
increased sensitivity to DSS-induced colitis in Nod2−/− mice.
Because both immune and colon structural (epithelial and stromal) cells express Nod2, we
performed bone marrow transplant experiments and generated Pglyrp3−/− >
Pglyrp3−/−Nod2−/−and Pglyrp3−/−Nod2−/− > Pglyrp3−/− chimeric mice to identify the source
of Nod2-deficient cells that mediate increased sensitivity to DSS-induced colitis. Our data
indicate that an unbalanced expression of Nod2 due to the lack of Nod2 expression in bone
marrow-derived cells combined with the expression of Nod2 in structural (radio-resistant)
cells in a Pglyrp3-deficient background results in the highest sensitivity to colitis. On the
contrary, the lack of Nod2 expression in structural cells combined with the expression of
Nod2 in bone marrow-derived cells results in intermediate sensitivity to colitis, and similar
to the sensitivity of mice lacking Nod2 in all cells. Finally, expression of Nod2 in all cells
results in the lowest sensitivity to colitis. These results suggest that expression of Nod2 in
bone marrow-derived cells is more important for protection against colitis than Nod2
expression in structural cells, and also that expression of Nod2 in structural cells has a
colitis-promoting effect, but only when Nod2 is not expressed in bone marrow-derived cells.
The reasons for the protection from colitis from bone marrow-derived Nod2 and the
susceptibility to colitis from structural cells-derived Nod2 (but only when bone marrow-
derived Nod2 is missing) are not clear and may include protective effects of cytokines from
bone marrow-derived cells or other cross-talk between these two cell types.
The role of Nod2 in intestinal disease is complex, often contradictory, and not clearly
understood. Different models have been proposed to explain the role of Nod2 in CD and in
animal models of colitis. One possible explanation is an impaired response of intestinal
mucosa and immune cells in Nod2-deficient individuals to intestinal bacteria resulting in an
inability to control microflora-induced intestinal damage. A second possible explanation is
dysbiosis in Nod2-deficient mice (43-46) and humans with Nod2 mutations (45), resulting in
more damaging bacteria in the terminal ileum. A third possible explanation is that Nod2 is a
negative regulator of TLR-signaling and that Nod2 deficiency results in increased TLR-
mediated responses to bacteria, which leads to damaging inflammation (42, 68, 69).
However, an inhibitory role of Nod2 in TLR-signaling is controversial and has been shown
by only one research group, whereas several investigators have determined that during acute
responses, Nod2 activation synergizes with TLRs to increase production of proinflammatory
cytokines (41, 70-72).
Our data support the first explanation and show that Pglyrp3-controlled changes in intestinal
microflora and Pglyrp3-controlled increases in colonic ATP promote colitis on Nod2−/−
background. Thus, Nod2 deficiency results in less efficient control of microflora-induced
damage, and one contributing factor is the higher sensitivity to apoptosis and ATP in the
colon on Nod2−/− than on Nod2+/+ background. Our data do not support the second and third
explanations, because Nod2 deficiency did not contribute to colitis-predisposing intestinal
microflora (Fig. 4), and because cytokine and chemokine responses of macrophages or
colonic cells to gut microflora were lower on Nod2−/− than on Nod2+/+ background (Fig. 5).
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In summary, the two innate immunity genes, Pglyrp3 and Nod2, synergistically protect mice
in an experimental model of colitis. A combined deficiency of Pglyrp3 and Nod2 results in
higher sensitivity to DSS-colitis due to a combination of factors, including higher apoptosis,
altered gut microbiota, and increased ATP in the colon. Pglyrp3 deficiency contributes
colitispredisposing intestinal microflora and increased intestinal ATP, whereas Nod2
deficiency contributes higher apoptosis and higher sensitivity to increased ATP and to
microflora.
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Figure 1. Pglyrp3−/−Nod2−/− mice are more susceptible to DSS-induced colitis than Pglyrp3 and
Nod2 single-deficient mice
WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice were treated with 5% DSS in
drinking water and development of colitis was evaluated. (A) DSS-treated mice were
monitored over time for survival, change in body weight, and stool and rectal bleeding. (B
and C) DSS-treated mice were sacrificed on day 7 of treatment and hematoxylin-eosin
stained sections of the colon were (B) qualitatively and (C) quantitatively evaluated for
severity of colitis. Epithelial cells (E), lamina propria (LP), goblet cells (G), muscularis
mucosa (MM), submucosa (SM), muscularis externa (ME), and inflammatory cell
infiltrations (IN) are indicated; size bar = 100 μm. The data are (A) mean ± SEM of 19-20
mice/group; and (B) representative images or (C) mean ± SEM from 4 mice/group.
Significance of differences between Pglyrp3−/−Nod2−/− and WT mice is indicated by
asterisks (*); and between Pglyrp3−/−Nod2−/− and Pglyrp3−/− is indicated by the number
sign (#); *, #, P ≤ 0.05; **, ##, P ≤ 0.005.
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Figure 2. Pglyrp3−/−Nod2−/− mice have higher permeability and increased apoptosis in the colon
(A to D) WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice were treated with 5% DSS
and (A) gavaged with FITC-dextran on days 0, 3, 6, and 7 and assayed for FITC-dextran in
the serum; (B) 4 days later injected with BrdU and colon sections were stained for BrdU; (C
and D) 4 days later colon sections were stained for (C) TUNEL; or (D) cleaved caspase-3.
(E) Pglyrp3−/− Nod2−/− mice were treated with 5% DSS and gavaged daily with the caspase
inhibitor Q-VD-Oph or with PBS for the control group and development of colitis was
monitored by survival, change in body weight, and stool and rectal bleeding scores or 4 days
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later colon sections were stained for TUNEL. The data are mean ± SEM of (A) 12, (B, C,
and D) 4 to 6, and (E) 9 to 10 mice/group for colitis and 6 mice/group for TUNEL staining;
representative histological images are shown in (B-D). Significance of differences for (A to
D) knockout versus WT mice or (E) inhibitor treated versus control group is indicated by
asterisks (*); and between Pglyrp3−/−Nod2−/− or Nod2−/− versus Pglyrp3−/− is indicated by
the number sign (#); *, #, P ≤ 0.05; **, ##, P ≤ 0.005.
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Figure 3. Pglyrp3−/−Nod2−/− mice express higher levels of chemokine and cytokine mRNA in the
colon following DSS treatment
WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/− mice were treated with 5% DSS for
indicated times and expression of inflammatory genes in the colon was measured by qRT-
PCR. The results are means ± SEM of the ratio of the amount of mRNA in DSS-treated to
untreated mice from 9 mice per group, 3 mice pooled per array. Significance of differences
between knockouts and WT mice is indicated by asterisks (*) and between Pglyrp3−/−
Nod2−/− and Pglyrp3−/− is indicated by the number sign (#); *, #, P ≤ 0.05; **, ##, P ≤
0.005. The data are selected from the 96 inflammatory gene expression array shown in
supplemental Table S1.
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Figure 4. Pglyrp3−/−Nod2−/− mice have changes in intestinal bacterial flora, however only
Pglyrp3-dependent changes contribute to the increased sensitivity to colitis in Pglyrp3−/− Nod2−/−
mice
(A) Changes in the composition of bacterial flora in the stools of WT and knockout mice in
all Eubacteria and the indicated bacterial groups, measured by qPCR; (B) WT germ-free
mice were treated with 4% DSS and gavaged daily with stool homogenates from
conventionally raised WT, Nod2−/−, Pglyrp3−/−, or Pglyrp3−/−Nod2−/− mice or (C) Nod2−/−
mice were pre-treated with antibiotics for 3 weeks and then gavaged daily with stool
homogenates from conventionally raised WT or Pglyrp3−/− and treated with 4% DSS.
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Development of colitis in B and C was evaluated by measuring survival, body weight, and
stool score. Gross rectal bleeding in mice gavaged with stools from Pglyrp3−/− mice but not
from WT mice is shown in (C). The results are means ± SEM of (A) 18 mice/group and (B
and C) 6 mice/group from 2 experiments. Significance of differences for (A) *, knockout
versus WT; (B) *, Pglyrp3−/− versus Nod2−/− and WT; #, Pglyrp3−/−Nod2−/− versus Nod2−/−
and WT; ^, Pglyrp3−/−Nod2−/− versus Pglyrp3−/−; (C) *, Pglyrp3−/− versus WT; *, #, ^, P ≤
0.05; **, ##, ^^, P ≤ 0.005.
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Figure 5. WT (Nod+/+) but not Nod2−/− macrophages and colon cells produce more chemokines
and cytokines in response to stools from Pglyrp3-deficient mice
(A) Colon cells and colon fragments or (B) bone marrow-derived macrophages from WT or
Nod2−/− mice were stimulated with stools from WT or Pglyrp3−/− mice or with PBS (no
stimulant). Supernatants were assayed for the indicated chemokines or cytokines. The results
are means ± SEM (N = 6 experiments); significance of differences for Nod2−/− versus WT
cells; *, P ≤ 0.05; **, P ≤ 0.005.
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Figure 6. Pglyrp3−/−Nod2−/− and Pglyrp3−/− mice have higher levels of ATP in the colon, and
intestinal ATP preferentially increases sensitivity of Nod2−/− mice to DSS-colitis
(A) Amounts of ATP in the stools of WT, Nod2−/−, Pglyrp3−/−, and Pglyrp3−/−Nod2−/−
mice. (B) WT and Nod2−/− mice treated with 5% DSS and gavaged with the ATP analog,
α,β-ATP, have lower survival and body weight, and higher stool scores than PBS-treated
mice, and Nod2−/− mice are more sensitive to ATP than WT mice. (C) Increased
percentages of the indicated cell types in colon lamina propria and mesenteric lymph nods
(MLN) in Nod2−/− mice, gated for CD45 or CD4. (D) Representative dot plots for Th17,
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Th1, and Th2 cells for the data shown in (C). The results are means ± SEM of (A) 6-8, (B)
10-11, and (C) 6-7 mice/group from 2 experiments. Significance of differences for (A)
knockouts versus WT; (B) *, **, ATP- versus PBS-treated Nod2−/− mice; ^, ^^, ATP- versus
PBS-treated WT mice; #, Nod2−/− versus WT ATP-treated mice; or (C) ATP versus PBS; *,
^, #, P ≤ 0.05; **, ^^, P ≤ 0.001.
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Figure 7. Lack of Nod2 in bone marrow-derived cells combined with presence of Nod2 in
structural cells predisposes Pglyrp3−/− mice to severe colitis
(A) Chimeric (Pglyrp3−/− > Pglyrp3−/−Nod2−/− and Pglyrp3−/−Nod2−/− > Pglyrp3−/−) and
transplanted control (Pglyrp3−/− > Pglyrp3−/− and Pglyrp3−/−Nod2−/− > Pglyrp3−/− Nod2−/−)
mice were treated with 4% DSS in drinking water and development of colitis was evaluated.
DSS-treated mice were monitored over time for survival, change in body weight, and stool
and rectal bleeding. The results are means ± SEM of 5-6 mice/group. Statistically significant
differences between the indicated groups are shown as *, P ≤ 0.05; **, P ≤ 0.005. (B)
Presence of Nod2 KO (1 kb amplified fragment) or Nod2 WT (300 bp amplified fragment)
alleles was assessed by PCR of genomic DNA from blood cells of chimeric
(Pglyrp3−/−Nod2−/− > Pglyrp3−/− and Pglyrp3−/− > Pglyrp3−/−Nod2−/−) or non-transplanted
Pglyrp3−/− and Nod2−/− mice.
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